Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study

The Evaluating Nilotinib Efficacy and Safety in Clinical Trials as First-Line Treatment (ENEST1st) study included 1089 patients with newly diagnosed chronic myeloid leukemia in chronic phase. The rate of deep molecular response (MR(4) (BCR-ABL1⩽0.01% on the International Scale or undetectable BCR-AB...

Descripción completa

Detalles Bibliográficos
Autores principales: Hochhaus, A, Rosti, G, Cross, N C P, Steegmann, J L, le Coutre, P, Ossenkoppele, G, Petrov, L, Masszi, T, Hellmann, A, Griskevicius, L, Wiktor-Jedrzejczak, W, Rea, D, Coriu, D, Brümmendorf, T H, Porkka, K, Saglio, G, Gastl, G, Müller, M C, Schuld, P, Di Matteo, P, Pellegrino, A, Dezzani, L, Mahon, F-X, Baccarani, M, Giles, F J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705425/
https://www.ncbi.nlm.nih.gov/pubmed/26437782
http://dx.doi.org/10.1038/leu.2015.270

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705425/
https://www.ncbi.nlm.nih.gov/pubmed/26437782
http://dx.doi.org/10.1038/leu.2015.270

Ejemplares similares